Healthcare Industry News:  Hi·Art 

Devices Oncology Distribution

 News Release - October 16, 2008

TomoTherapy and Hitachi Medical Corporation Sign Letter of Intent for Distribution in Japan

MADISON, Wisconsin – Oct. 16, 2008 –(HSMN NewsFeed)--TomoTherapy Incorporated (NASDAQ: TOMO) announced today that it has signed a letter of intent with Hitachi Medical Corporation (HMC) to distribute the Hi·Art® cancer treatment system in Japan.

“We are proud to be in discussions with Hitachi Medical Corporation, a highly-respected Japanese company with an excellent national service infrastructure,” said TomoTherapy CEO Fred Robertson, M.D. “HMC should prove to be an ideal partner for TomoTherapy, and for our valued Japanese customers.”

Terms of the agreement between TomoTherapy and HMC are being finalized. Details will be announced upon contract signing. The partnership between TomoTherapy and Hitachi Medical Corporation is expected to commence by the end of 2008.

About Hitachi Medical Corporation

Hitachi Medical Corporation is a full-line supplier of medical equipment in Japan and a subsidiary of Hitachi, Ltd., which is a global electronics company with more than US$100 billion of sales in consolidated basis and about 390,000 employees worldwide.

About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, markets and sells the TomoTherapy® Hi·Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi·Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO.


Source: TomoTherapy

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.